Company PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for PYC Therapeutics Limited

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:45 2024-04-19 am EDT			5-day change	1st Jan Change
0.091 ^AUD	-4.21%		-9.00%	-17.27%

Apr. 10	PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced	MT
Mar. 18	PYC Therapeutics Raises AU$40 Million via Entitlement Offer	MT

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company, which offers ribonucleic acid (RNA) therapeutics in patients with unmeet genetic diseases. The Company has RNA targeted therapeutics design capabilities to deliver technologies based on cell penetrating peptides (CPPs) and peptide conjugated phosphorodiamidate morpholino oligomer (PPMOs). The Company develops a pipeline of therapies, including two programs, which are focused on inherited eye diseases and preclinical discovery programs, which are focused on neurodegenerative and kidney diseases. The Companyâs lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate PYC-001, which is focused on treating autosomal dominant optic atrophy (ADOA). Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The Company's discovery and laboratory operations are located in Australia.

Number of employees: 5

Managers	Title	Age	Since
Rohan Hockings CEO	Chief Executive Officer	40	-
Andrew Taylor DFI	Director of Finance/CFO	-	-
Kevin Hart DFI	Director of Finance/CFO	62	17-07-23
Paula Cunningham CTO	Chief Tech/Sci/R&D Officer	-	-
Sue Fletcher CTO	Chief Tech/Sci/R&D Officer	-	18-12-31
Sri Mudumba PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Michael Rosenblatt BRD	Director/Board Member	76	21-03-16
Jason Haddock BRD	Director/Board Member	54	21-03-28
Alan W. Tribe CHM	Chairman	76	18-04-10
Rohan Hockings CEO	Chief Executive Officer	40	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,732,867,135	1,770,806,760 ( 47.44 %)	0	47.44 %

Name	Equities	%	Valuation
Australia Land Pty Ltd. 32.95 %	1,537,267,467	32.95 %	82 M $
Sietsma Holdings Pty. Ltd. 6.074 %	283,400,000	6.074 %	15 M $
McCusker Holdings Pty Ltd. 3.909 %	182,395,876	3.909 %	10 M $
Bernard Hockings 3.550 %	165,650,936	3.550 %	9 M $
METCASH LIMITED 3.329 %	155,345,202	3.329 %	8 M $
Trexon Pty Ltd. 3.329 %	155,345,202	3.329 %	8 M $
Runcton Pty Ltd. 3.329 %	155,345,202	3.329 %	8 M $
Stockbridge Corp. Pty Ltd. 3.329 %	155,345,201	3.329 %	8 M $
Datamatch Pty Ltd. 1.301 %	60,714,300	1.301 %	3 M $
Titan Bioventures Management Pty Ltd. 1.281 %	59,788,413	1.281 %	3 M $

PYC Therapeutics Ltd.

Harry Perkins Institute 6 Verdun Street

6009, Nedlands

http://www.pyctx.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.095 AUD

Average target price

0.345 AUD

Spread / Average Target

+263.16%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
PYC THERAPEUTICS LIMITED	-17.27%	274M
IQVIA HOLDINGS INC.	-1.82%	41.35B
LONZA GROUP AG	+42.44%	40.38B
MODERNA, INC.	+2.56%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.36B
MEDPACE HOLDINGS, INC.	+22.12%	11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.68B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.15B

Other Biotechnology & Medical Research